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Abstract
Background: Histidine–tryptophan–ketoglutarate (HTK) cardioplegia for myo-
cardial protection obviates the need for maintenance cardioplegia doses, and thus
allows for greater focus on procedure accuracy. The aim of this meta‐analysis is to
evaluate the safety and efficacy of HTK versus multidose cardioplegias during
cardiac surgery in an adult population.
Methods: Electronic searches were performed using PubMed, Science Direct, and
Google Scholar databases. The key search terms included HTK cardioplegia AND
cardiac surgery AND adult. This was followed by a meta‐analysis investigating
cardiopulmonary bypass (CPB) duration, cross‐clamp duration, spontaneous defi-
brillation, inotropic support, mortality, atrial fibrillation, creatine kinase muscle
brain band (CK‐MB) and troponin I (TnI).
Results: Seven randomized controlled trials (n = 804) were analyzed. Spontaneous
defibrillation following aortic cross‐clamp removal significantly favored HTK (odds
ratio [OR], 2.809; 95% confidence interval [CI], 1.574 to 5.012; I2 = 0%; p < .01).
There were no other notable significant differences between HTK and multidose
cardioplegia in any of the parameters measured. In particular, the OR for mortality
was 1.237 (95% CI, 0.385 to 3.978; I2 = 0%; p = .721) and the mean difference for
CPB duration overall was 2.072min (95% CI, −2.405 to 6.548; I2 = 74%; p = .364).
Conclusion: HTK is safe and effective during adult cardiac surgery when compared
with multidose cardioplegias for myocardial protection during surgical correction of
acquired pathology in the adult population. HTK may, therefore, be suitable for
complex cases or those of extensive duration, without the prospect of increased
postoperative morbidity or mortality.
K E YWORD S
adult, cardiac surgery, cardioplegia, HTK, multidose
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
© 2021 The Authors. Journal of Cardiac Surgery published by Wiley Periodicals LLC
1 | INTRODUCTION
Myocardial protection is of concern to the cardiac surgical team during
cardiopulmonary bypass (CPB). CPB was first demonstrated by Gibbon in
1954 as a mechanism to prevent major organ ischemia during asystole.
Protection was not, however, sustainable for the duration of complex
cardiac correction procedures, with an upper range of postoperative in‐
hospital mortality of 65%.1 Cardiac examination post‐mortem revealed
“stone heart”—irreversible myocardial contraction from ATP‐mediated
actin–myosin coupling, with failure of actin–myosin uncoupling due to
ATP depletion.2 This low level of success was thought to be associated
with the high concentration of citrate leading to chelation of magnesium
and calcium.3 However, the idea of using moderately elevated potassium
re‐emerged in the 1970s.3 One of the foremost proponents of crystalloid
hyperkalemic cardioplegia was the Bretschneider group in Germany. In
1980, they devised the histidine–tryptophan–ketoglutarate (HTK) cardi-
oplegia, which is the subject of this meta‐analysis.3
HTK (branded as Custodiol® by Essential Pharmaceuticals LLC),
has been presented by industry to surgeons as an alternative solution
that exceeds other cardioplegias in myocardial protection.4 This claim
relies on the single‐dose administration of HTK compared with other
multidose cardioplegias (MDC), sparing time in the adjustment of
equipment during cardioplegia re‐administration, allowing greater
time to operate and thus a decreased CPB duration.5 Other benefits
include a lower concentration of sodium, calcium, and potassium
compared with other cardioplegias with cardiac arrest arising from
the deprivation of sodium.5 Finally, histidine is thought to aid buf-
fering, mannitol and tryptophan to improve membrane stability, and
ketoglutarate to help ATP production during reperfusion.6
This is the first meta‐analysis to solely focus on HTK versus MDC
during cardiac surgery in the adult‐acquired disease population. A meta‐
analysis by Gambardella et al.7 in 2019 claimed to investigate single
dose versus MDC in the adult population; however, the inclusion of
Careaga et al.8 which contained both adult and pediatric populations
reduces the applicability of their findings to the clinical landscape of
adult cardiac surgery. Our meta‐analysis also includes the findings of
Vivacqua et al.9 Vivacqua et al.9 was submitted for publication 5 days
after Gambardella et al.,7 and so was not included in their analysis. In
addition, our meta‐analysis solely focuses on randomized controlled
trials (RCTs; Gambardella'a included both RCTs and propensity‐
matched studies). Most importantly, we supply new data on more out-
comes and include subgroup analysis according to surgery type.
It is, therefore, the aim of this meta‐analysis to define and
quantify the safety and efficacy of HTK to other cardioplegias during
adult cardiac surgery.
2 | METHODS
This is a meta‐analysis. A meta‐analysis involves the pooling of data
from already published trials. As such, therefore, no ethical approval
and no informed consent is required.
As per many of our previous surgical data analyses,10,11 this
systematic review and meta‐analysis was performed in accordance
with the PRISMA (preferred reporting items for systematic reviews
and meta‐analyses) guidelines (see Supporting Information files).
2.1 | Search strategy
To identify potential studies, systematic searches were carried out using
PubMed, Science Direct, and Google Scholar. The search was supple-
mented by scanning the reference lists of eligible studies. The search
strategy included the key concepts of “Custodiol versus Blood,” “HTK
solution versus blood,” “Bretschneider's solution versus blood,” “Custodiol
versus crystalloid,” “HTK versus crystalloid,” “Bretschneider's solution
versus crystalloid,” AND “Cardiac Surgery” AND “Cardioplegia.” (see
Supporting Information file for the search strategy). All identified papers
were assessed independently by two reviewers. A third reviewer was
consulted to resolve disputes. Searches of published papers were con-
ducted up until October 1, 2020. Data were extracted using predesigned
extraction tables.
2.2 | Types of trials to be included and excluded
Included trials were those that directly compared the use of HTK versus
any other type of MDC in open‐heart surgery. There were no language
restrictions. Animal studies and review papers were excluded. Studies
that did not have any of the desired outcome measures were excluded.
Incomplete data, or data from an already included study, were excluded.
Other treatment modalities and interventions for coronary artery disease
such as percutaneous coronary intervention and valvular disease such as
transcatheter aortic valve intervention were excluded.
2.3 | Participants/population
This meta‐analysis analyzed RCTs of both male and female adult
(≥8 years) patients with either coronary artery disease or valvular
disease who were undergoing cardiac surgery using either HTK or
other types of MDC.
2.4 | Intervention(s) and exposure(s)
This meta‐analysis considered all RCTs where HTK or another type of
MDC were used in either coronary artery bypass graft (CABG) or in
patients being treated for valvular disease. This specifically included all
RCTs where the intention was to carry out cardiac surgery using HTK
cardioplegia.
2.5 | Search results
Our initial search found 361 articles of which 330 were excluded on the
basis of title and abstract and a further 14 duplicate studies were ex-
cluded. A further six studies were excluded as they were investigating
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pediatric cases; one study was excluded as it had a mixed population;
and, three studies were excluded because they did not use HTK (-
Figure S1). Seven studies were included in our analysis.12–18
2.6 | Outcomes
The primary outcomes analyzed were CPB time, aortic cross‐clamp
time, spontaneous defibrillation (spontaneous return of heartbeat),
inotropic support, mortality, atrial fibrillation (AF), creatine kinase
muscle brain band (CK‐MB), and troponin I (TnI).
2.7 | Risk of bias (quality) assessment
The risk of bias was assessed using a modified Jadad scale for ran-
domized controlled trials.19 Publication bias was investigated using
funnel plots.20
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Abbreviations: AF, atrial fibrillation; CABG, coronary artery bypass graft; CPB, cardiopulmonary bypass; CK‐MB, creatine kinase myocardial band;
HTK, histidine–tryptophan–ketoglutarate; IABP, intra‐aortic balloon pump; MDC, cardiopulmonary bypass; NR, not reported; TnI, troponin I.
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2.8 | Data synthesis
Odds ratios (OR) were calculated for dichotomous data. Continuous
data were compared using mean differences (MD; CPB duration,
cross‐clamp duration, TnI) and standardized mean difference (SMD;
CK‐MB). Where necessary medians and interquartile ranges were
converted into means and SDs using the method of Hozo et al.21 All
analyses were conducted using Comprehensive Meta‐Analysis
(CMA) version 3. Heterogeneity was quantified using the Cochrane
Q test22 and all comparisons were made using random effects. We
used a 5% level of significance and 95% confidence intervals (CIs);
figures were produced using CMA. Ideally, the results of all trials
carried out to investigate the effects of HTK in comparison to other
types of cardioplegia would be published. Unfortunately, in reality,
not all trials are published which may lead to selective reporting or
publication bias. This can be detected in a funnel plot that is
asymmetrical.
3 | RESULTS
The seven studies9,12–18 included in the analysis had an aggregate of
804 participants, 412 of whom were HTK patients versus 391 who
received MDC. The characteristics of the included studies are sum-
marized in Table 1. The excluded RCTs and reasons for exclusion are
listed in Table S1. The results are summarized with perioperative
comparisons leading, followed by intraoperative variables and finally
cardiac biomarkers. A summary of all the results can be seen in
Table 2.
3.1 | CPB time
Seven studies involving 444 patients had their CPB duration mea-
sured (Figure 1). The overall MD was 2.103 min with 95% CI
of −2.329 and 6.536; p = .352. Heterogeneity (I2) was 77.7% and
p < .001. There was, therefore, no overall significant difference in
CPB time between HTK and other cardioplegias in our population.
Subgroup analysis for CABG (HTK, n = 165; MDC, n = 150) had an
MD of 8.291 min, with 95% CI of 0.033 and 16.549; p = .049;
I2 = 30% and p = .255. In this analysis, CPB time was shorter for
MDC. Subgroup analysis for valvular population (HTK, n = 179;
MDC, n = 124) had an MD of −0.401min, with 95% CI of −5.655,
4.853; p = .881; I2 = 85.3% and p < .001. There was, therefore, no
significant difference in CPB time between HTK and MDC in the
valvular population.
3.2 | Aortic cross‐clamp time
Seven studies involving 668 patients measured the aortic cross‐
clamp duration (Figure 2). The overall MD was 0.276min, with 95%
CI of −2.569 and 3.120; p = .849; I2 = 60.4% and p = .019. There was,
therefore, no significant difference in aortic cross‐clamp time
between HTK and other cardioplegias in our population. Subgroup
analysis for the CABG population (HTK, n = 165; MDC, n = 150) had
an MD of 1.852min, 95% CI of −4.34, 8.044; p = .558; I2 = 65.1% and
p = .057. There was, therefore, no significant difference in aortic
cross‐clamp time between HTK and MDC in the CABG population.
Subgroup analysis for the valvular population (HTK, n = 179; MDC,
n = 124) had an MD of −0.146min, 95% CI of −3.348, 3.056; p = .929;
I2 = 66.4% and p = .03. There was, therefore, no significant difference
in aortic cross‐clamp time between HTK and MDC for the valvular
population.
3.3 | Spontaneous defibrillation (spontaneous
return of heartbeat)
Two studies involving 286 patients were measured for the incidence
of spontaneous defibrillation (Figure 3). The OR for the comparison
was 2.809, with 95% CI of 1.574, 5.012; p < .001; I2 = 0% and
p = .754. Spontaneous defibrillation, therefore, significantly favored
HTK over MDC.
3.4 | Inotropic support
Four studies involving 306 patients measured the incidence for
postoperative inotropic support (Figure 4). The OR was 1.5, with
95% CI of 0.742, 3.032; p = .259; I2 = 44.5% and p = .145. There was
therefore no significant difference in the use of inotropes between
HTK and MDC. Subgroup analysis for the CABG population (HTK,
n = 80; MDC, n = 80) had an OR of 0.616, 95% CI of 0.048, 7.965;
p = .24; I2 = 27.5% and p = .24. There was, therefore, no significant
difference in the incidence of inotropic support between HTK and
MDC in the CABG population. Subgroup analysis for the valvular
population (HTK, n = 93; MDC, n = 93) had an OR of 1.613, 95% CI of
0.776, 3.354; p = .20; I2 = 37.9 and p = .204. There was, therefore, no
significant difference in the incidence of inotropic support between
HTK and MDC in the valvular population.
3.5 | Mortality
Three studies involving 285 patients reported the incidence of
mortality (Figure 5). The OR was 1.237, with 95% CI of 0.385, 3.978;
p = .721; I2 = 0% and p = .605. There was, therefore, no significant
difference in the incidence of mortality between HTK and MDC.
3.6 | AF
Four studies involving 306 patients reported the incidence of post-
operative AF (Figure 6). The OR was 0.809, with 95% CI of 0.511,
1.281; p = .366; I2 = 13.9% and p = .323. There was, therefore,
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no significant difference in the incidence of postoperative AF in ei-
ther the HTK or other cardioplegia groups in our population. A
subgroup analysis of the CABG population (HTK, n = 80; MDC,
n = 80) had an OR of 1.188, 95% CI of 0.615, 2.294; p = .608; I2 = 0%
and p = .684. There was, therefore, no significant difference in the
incidence of postoperative AF between HTK and MDC in the CABG
population. Subgroup analysis for the valvular population (HTK,
n = 93; MDC, n = 93) had an OR of 0.562, 95% CI of 0.296, 1.067;
p = .078; I2 = 0% and p = .948. There was, therefore, no significant
difference in the incidence of postoperative AF between HTK and
MDC in the valvular population.
3.7 | Release of CK‐MB
Five studies involving 335 patients measured postoperative serum
CK‐MB concentrations (Figure 7). The SMD was −0.046, with 95% CI of
−0.27, 0.178; p= .687; I2 = 0% and p= .44. There was, therefore, no sig-
nificant difference in serum CK‐MB between HTK and MDC. Subgroup
analysis for the CABG population (HTK, n=101; MDC, n=101) had an
SMD of 0.009, with 95% CI of −0.267, 0.286; p= .947; I2= 0% and
p= .521. There was, therefore, no significant difference in the serum
CK‐MB release between HTK and MDC in the CABG population. A
subgroup analysis for the valvular population (HTK, n=93; MDC, n=90)
had an SMD of −0.153, with 95% CI of −0.538, 0.231; p= .435; I2 = 41.7%
and p= .19. There was, therefore, no significant difference in the plasma
CK‐MB release between HTK and MDC in the valvular population.
3.8 | Release of TnI
Three studies involving 285 patients measured the postoperative serum
TnI concentration (Figure 8). The MD was −1.424ng/ml, with 95% CI
of −7.747, 4.898; p= .659; I2 = 78.4% and p= .01. There was, therefore,










CABG MD= 8.291min 0.033 16.549 .049 30 .255
Valve MD= −0.401min −5.655 4.853 .881 85.3 .001
Overall MD = 2.103min −2.329 6.536 .352 77.7 .001
Aortic cross‐clamp time
CABG MD= 1.852min −4.34 8.044 .558 65.1 .057
Valve MD= −0.146min −3.348 3.056 .929 66.4 .03
Overall MD = 0.276min −2.569 3.120 .849 60.4 .019
Spontaneous return of heartbeat
Overall OR = 2.809 1.574 5.012 <.001 0 .754
Inotropic support
CABG OR = 0.616 0.048 7.965 .71 27.5 .24
Valve OR = 1.613 0.776 3.354 .2 37.9 .204
Overall OR = 1.5 0.742 3.032 .259 44.5 .145
Mortality
Overall OR = 1.237 0.385 3.978 .721 0 .605
Incidence of atrial fibrillation
CABG OR = 1.188 0.615 2.294 .608 0 .684
Valve OR = 0.562 0.296 1.067 .078 0 .948
Overall OR = 0.809 0.511 1.281 .366 13.9 .323
CK‐MB
CABG SMD= 0.009 −0.267 0.286 .947 0 .521
Valve SMD= −0.153 −0.538 0.231 .435 41.7 .19
Overall SMD= −0.046 −0.27 0.178 .687 0 .44
Tn I
Overall MD = −1.424 ng/ml −7.747 4.898 .659 78.4 .01
Abbreviations: CABG, coronary artery bypass graft; CK‐MB, creatine kinase myocardial band; lower
limit, lower 95% confidence interval; MD, mean difference; OR, odds ratio; SMD, standardized mean
difference; TnI, troponin I; upper limit, upper 95% confidence interval.
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F IGURE 1 CPB time. On the left is a table displaying the mean difference, lower limit, upper limit, z value, and p value for each of the pooled
studies with the final line presenting the overall statistics. On the right is a forest plot, which displays the mean difference (squares) and 95%
CIs (whiskers) for each of the individual studies. Also shown is the overall mean difference (diamond) where the width of the diamond
represents the 95% CIs. For the sake of clarity, the overall results with heterogeneity scores have been written below the forest plot.
CABG, coronary artery bypass graft; CPB, cardiopulmonary bypass; CI, confidence interval; HTK, histidine–tryptophan–ketoglutarate
cardioplegia; MD, multidose cardioplegia
F IGURE 2 Cross‐clamp time. All details as in Figure 1
F IGURE 3 Spontaneous return of heartbeat. All details as in Figure 1, except that the effect size shown is the odds ratio
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no significant difference in the serum TnI release between HTK
and MDC.
3.9 | Study quality
The modified Jadad scale was used to assess study quality. The median
score was 4 indicating studies were of moderate quality. None of the
studies performed blinding and only one of the studies used an intention
to treat analysis. On the positive side, no studies had incomplete data and
all groups were matched at baseline. It was not possible to carry out
subgroup analysis based on the quality of the studies as there was in-
sufficient spread on either side of the median score.
4 | DISCUSSION
Cardioplegia has evolved since the inception of cardiac surgery itself.
The current state of the industry sees several cardioplegia products
presented to surgeons; with data often focussed only on areas of
F IGURE 4 Inotropic support. All details as in Figure 3
F IGURE 5 Mortality. All details as in Figure 3
F IGURE 6 Incidence of atrial fibrillation. All details as in Figure 3
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clear statistical advantage, with the present data of HTK in cardiac
transplantation exemplifying this.5 The lack of data presented by
industry on the performance of HTK in the broader cardiothoracic
arena, however, suggests that a review of the current literature is
required to establish a fair consensus on the value of HTK in all
cardiac surgery, with particular emphasis in this paper on the
treatment of acquired pathology in adults. By producing this meta‐
analysis, we met our objective to determine whether superiority
exists in HTK compared with other marketed cardioplegias in the
adult population, with pooled data for several outcomes in both
perioperative and postoperative phases, clinical and basic sciences;
we have produced several parameters by which we can contribute to
the discussion of HTK's role in cardiac surgery.
While major adverse cardiac and cerebrovascular events were
rare (with stroke being a never event in our population), mortality
was reported in both investigation groups. The statistical insignif-
icance between cardioplegia groups for mortality suggest the cause
of death in each case was unrelated to the chosen cardioplegia, with
authors attributing preoperative ventricular impairment,15 post-
operative low cardiac output syndrome,16 graft thrombosis,14 and
subsequent continued infarction13 as the cause of death in their
respective populations. Previous research suggests that neither
cardioplegia type nor technique are significantly influential on the
incidence of myocardial ischemia following surgery,23 and this would,
therefore, support our population authors' death attributions and
the statistical findings of our pooled data.
The incidence of spontaneous defibrillation was shown to sig-
nificantly favor the HTK group in our population. This analysis was
derived from a moderate population size, and may suggest that HTK
has greater protective qualities to the myocardium during aortic
cross‐clamp phase.
The incidence of postoperative administration of inotropes and
postoperative AF also suggests the protective effect of cardioplegia
on myocardial physiology and cardiomyocyte biochemistry. Our
findings found insignificant differences between HTK and MDC for
both parameters, suggesting that adverse events are due to other
factors (such as perioperative myocardial handling, or cardioplegia
technique)24 rather than cardioplegia type. This is supported by our
pooling of biochemical data, which found insignificant differences in
TnI and CK‐MB, suggesting that, while both were observed to be
elevated in each study following surgery, there was no significantly
greater concentration in either the HTK or multidose populations.
The combination of pooled clinical and biochemical findings shows
that, while myocardial physiology and biochemistry are disrupted
perioperatively, these cases are sporadic and cannot be attributed to
cardioplegia type in our population.
Duration of perioperative phases of surgery has been widely
demonstrated to influence convalescence following surgery, for
F IGURE 7 Creatine kinase myocardial band. All details as in Figure 1, except that the effect size shown is the standardized mean difference
F IGURE 8 Troponin I. All details as in Figure 1
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example, the incidence of stroke.25 CPB duration, during which patient
blood is exposed to foreign surfaces via the CPB machinery, has corre-
lated with several coagulopathic and pro‐inflammatory responses within
the body.26 Statistically, retrospective surgical data analysis presents an
issue of bias when measuring CPB duration. Surgeon bias, whereby cases
with a greater anticipated duration are assigned single‐dose cardioplegias
(such as HTK, or del Nido cardioplegia) instead of multidose (i.e., blood or
other crystalloid), often results in a statistically significant difference
being found in CPB duration, favouring multidose solutions.11,13 As a
result of this observation, we selected randomized, prospective trials
only, to ensure that any statistical difference in CPB duration would be
the result of cardioplegia, and not procedure. Through this approach, we
determined no statistically significant difference in either overall CPB
duration, or indeed in the aortic cross‐clamp duration. A commonly cited
advantage of HTK is its single‐dose administration,4 and with our insig-
nificant findings in perioperative phase durations, it is reasonable to
suggest that surgeons opt for HTK when performing cases of complexity
or extensive duration, owing to the lack of inconvenience bestowed by
readministration of this cardioplegia.
We originally hypothesized that statistically significant differences in
our clinical endpoints may be found by stratifying our data according to
aortic cross‐clamp duration, that is, ischemic time of >90min versus is-
chemic time of <90min. However, screening of participating literature
revealed, at present, only one RCT18 (n=107) with mean cross‐clamp
duration of >90min, which alone would render statistically meaningless
data. Surgical data analysis relies on regular publication from individual
centers; greater clarity will be derived on our cross‐clamp duration hy-
pothesis following the publication of further RCT data.
In a recent meta‐analysis, Gambardella et al.7 reported that del
Nido cardioplegia was significantly favored in several of the out-
comes investigated including spontaneous defibrillation. In contrast,
our meta‐analysis was solely focused on HTK cardioplegia in com-
parison to MDC and has shown that spontaneous defibrillation is
higher in the HTK group. This and other limitations in Gambardella
et al.,7 as described in Section 1, suggest that it is too soon to be
referring to superiority.
4.1 | Limitations
There was insufficient data to stratify clinical parameters according
to cross‐clamp duration time. It was hypothesized that statistical
significance may exist in our clinical endpoints, should the data be
stratified according to studies with a mean cross‐clamp duration
>90min. However, only one study in our population met this cri-
terion, and therefore, a meaningful analysis could not be performed.
4.2 | Conclusions
HTK and MDC are safe and effective in the myocardial protection of
adult patients undergoing cardiac surgery. HTK was shown to be as
effective as multidose in most clinical parameters measured.
Spontaneous defibrillation occurred significantly more often in
the HTK group following aortic cross‐clamp removal. More data
measuring this parameter are needed to determine the external
validity of this finding.
Single‐dose administration of HTK is, therefore, the only sig-
nificant difference in our population. Surgeon preference, anticipated
procedure duration, and case complexity should therefore determine
the selection of HTK when planning procedures.
More data are currently needed for procedures with a cross‐
clamp duration >90min, to ascertain whether statistical significance
exists between HTK and MDC in procedures over 90min.
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